Dr. Albert Bourla, The CEO and Chairman of Pfizer 

On a weekday morning in a haematology day unit, a patient receives a first priming dose of a bispecific antibody and is observed for signs of cytokine release. The chairs around her are full of people receiving other treatments, and the nurse watching her is also covering two other bays. Nothing in the scene looks like a medical breakthrough. It looks like a capacity problem, and that is the right place to begin with the topline results Pfizer announced this week for elranatamab, marketed as Elrexfio, in relapsed or refractory multiple myeloma.

The MagnetisMM-32 trial involved 523 adults whose disease had progressed after treatment with anti-CD38 therapy and lenalidomide. Participants were randomly assigned to receive either elranatamab or one of three established treatment regimens selected by their investigators. It met its primary endpoint of progression-free survival at interim analysis. More than three quarters of patients on the drug had not progressed or died, with an estimated 68 per cent progression-free at 18 months. Overall survival data are immature. Grade 3 or higher infections occurred in 27.5 per cent of patients on elranatamab against 18.1 per cent on comparator regimens, although fatal infections were less frequent, at 0.8 per cent against 1.6 per cent. The trial was open-label. Pfizer maintains that findings from MagnetisMM-32, alongside earlier results from MagnetisMM-5, support introducing BCMA-targeted therapy earlier in the myeloma treatment pathway.

That argument deserves attention in Britain because the patient population in the trial is one the NHS is itself creating. As anti-CD38 antibodies and lenalidomide move into earlier stages of treatment, more patients are progressing after already receiving these established therapies. Around 6,000 people are diagnosed with myeloma in the UK each year, and the disease typically requires multiple lines of treatment over several years. A continuous therapy placed earlier in that sequence is taken for longer by more people, so cost and workload accumulate in ways a single appraisal can understate.

The operational picture is mixed. An off-the-shelf antibody avoids the manufacturing slots, apheresis capacity and small number of specialist centres on which CAR-T therapy depends, and that is a real advantage for equitable access. It does not make delivery simple. Step-up dosing requires patient observation, while frequent weekly visits during the initial treatment phase add to demand for infusion chairs and clinical staff. Infection risks also necessitate ongoing prophylaxis and close monitoring. Trusts that already struggle to protect day-unit capacity for chemotherapy and immunotherapy will have to decide where this work sits and who is trained to recognise toxicity at a distance from the specialist centre. Regional cancer networks are best placed to determine how treatment should be delivered locally, but many have yet to establish a clear approach.

‍

Appraisal will be the first formal test. NICE will be asked to judge a drug on progression-free survival with overall survival still immature, in an open-label design, against a comparator that is investigator's choice among three regimens. Those regimens may not mirror the mix of treatments used in English practice, and the committee will want to understand how much of the observed benefit survives that translation.Pfizer will also be seeking a recommendation that supports its ambition to use elranatamab earlier in the treatment pathway. A managed access agreement tying funding to outcomes captured through NHS records could benefit both parties, provided the necessary data infrastructure is in place to support reliable collection and analysis.

There is also a commercial context. Large manufacturers, Pfizer among them, have argued publicly that the UK undervalues new medicines and have adjusted their investment decisions accordingly. NICE’s recent increase in its cost-effectiveness threshold was intended to shift that assessment. A high-profile oncology product moving through appraisal will show quickly whether the revised terms translate into faster, more predictable access or whether familiar friction returns.

For NHS leaders, the sensible step is to model day-unit demand and infection-management pathways before a recommendation arrives, since a positive decision will not wait for the workforce to catch up.For policymakers, the priority is ensuring that managed access arrangements produce reliable, actionable real-world evidence. For industry, the message is equally clear: demonstrating clinical efficacy is only part of the case for adoption; showing that a treatment can be delivered effectively within the NHS is just as important.

The trial indicates that elranatamab can help control disease in a substantial proportion of patients. Whether British patients benefit will depend on chairs, nurses, monitoring protocols and data systems that no trial protocol describes.